Which of the following statement(s) is/are true concerning pharmacologic agents used to accelerate wound healing?

b. PDGF (platelet-derived growth factor) promotes fibroblast proliferation, chemotaxis, and collagenase synthesis

c. PDGF has been demonstrated in a number of clinical trials to promote healing in chronic wounds

Currently there are no approved clinical agents that accelerate normal healing. Although a number of clinical trials are in progress, no agents are currently approved. PDGF (platelet-derived growth factor) accelerates wound healing by promoting fibroblast proliferation and chemotaxis and collagenase synthesis. Clinical trials have demonstrated that PDGF has accelerated healing in patients with chronic wounds such as pressure sores and diabetic ulcers. Growth hormone has been successfully used in some situations to reverse the catabolic effect of severe injuries. Wound healing is fundamentally an anabolic event, and in the setting of a severe burn, growth hormone administration significantly accelerates donor site healing, presumably due to its effects in minimizing catabolism.